Elsulfavirine (Elpida®): First Global Approval – a potential aid to the HIV epidemic in Russia

Elsulfavirine (Elpida®): First Global Approval – a potential aid to the HIV epidemic in Russia

The recent first global approval of elsulfavirine has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Elsulfavirine (Elpida®): First Global Approval – a potential aid to the HIV epidemic in Russia”

Enasidenib (Idhifa®): First Global Approval – first-in-class, precision therapy for patients with mutated AML

Enasidenib (Idhifa®): First Global Approval – first-in-class, precision therapy for patients with mutated AML

The recent first global approval of enasidenib has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Enasidenib (Idhifa®): First Global Approval – first-in-class, precision therapy for patients with mutated AML”

Neratinib (Nerlynx™): First Global Approval – a new adjuvant option for HER2+ve breast cancer patients – but has it bottomed out before it’s begun?

Neratinib (Nerlynx™): First Global Approval – a new adjuvant option for HER2+ve breast cancer patients – but has it bottomed out before it’s begun?

The recent first global approval of neratinib has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1], based on the development milestones tracked in AdisInsight[2]. Continue reading “Neratinib (Nerlynx™): First Global Approval – a new adjuvant option for HER2+ve breast cancer patients – but has it bottomed out before it’s begun?”